GLP-2 (10mg)

Recent research & studies

• Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice. — PubMed • Ding M et al. • iScience • 2026 Sep 18

  Chronic kidney disease is a major health burden. Given the therapeutic potential of GLP-1 receptor agonists (semaglutide, tirzepatide, and retatrutide) in diabetic nephropathy, we evaluated their anti-fibrotic and anti-inflammatory effects in non-diabetic renal fibrosis using HK-2 cells and murine UUO…

• Weight loss outcomes with tirzepatide in women with and without self-reported polycystic ovary syndrome. — PubMed • Clift AK et al. • J Endocr Soc • 2026 Sep

  Context: Weight management is key to managing polycystic ovary syndrome (PCOS) and overweight/obesity but is challenging for many. Evidence regarding tirzepatide's efficacy in women with polycystic ovary syndrome is limited. Objectives: To quantify the effectiveness of tirzepatide for weight loss…

• Incretin Therapies in Obesity-related HFpEF — ClinicalTrials.gov • Recruiting • Phase4 • August 24, 2026

  The central hypothesis to be tested is that patients with obesity and heart failure with preserved ejection fraction (HFpEF) prescribed tirzepatide will demonstrate reductions in measured plasma volume. In conjunction with state-of-the-art body composition analysis and measures of adipokines, this…

• Avexitide for Treatment of Post-Bariatric Hypoglycemia — ClinicalTrials.gov • Active Not Recruiting • Phase3 • August 24, 2026

  AVX-001 (LUCIDITY) is a Phase 3 study to evaluate avexitide compared to placebo in participants with post bariatric hypoglycemia (PBH) related to Roux-en-Y gastric bypass (RYGB). The study will assess avexitide compared to placebo for safety and efficacy, measured by…

• Efficacy of a Dietary Supplement for Telogen Effluvium Associated With GLP-1 Receptor Agonist Use: A Clinical, Subjective, and Trichogram Evaluation — ClinicalTrials.gov • Not Yet Recruiting • Na • August 24, 2026

  A single-center, open-label clinical study to evaluate whether a dietary supplement can reduce hair loss in women with GLP-1-associated telogen effluvium. Participants will use the supplement for 120 days. Researchers will evaluate hair loss, hair density, and hair growth through…

• Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib — ClinicalTrials.gov • Not Yet Recruiting • Phase1 • August 24, 2026

  The proposed study seeks to address a critical gap in the management of lorlatinib-induced metabolic derangements, particularly rapid weight gain, which can adversely affect treatment adherence, dosing and ultimately patient outcomes. In this study patients with non-small cell lung cancer…

These are third-party research studies presented for informational purposes. They are not endorsements and do not constitute medical advice or claims about any product.